van der Veen, Elly L.
Antunes, InĂªs F.
Maarsingh, Petra
Hessels-Scheper, Janet
Zijlma, Rolf
Boersma, Hendrikus H.
Jorritsma-Smit, Annelies
Hospers, Geke A. P.
de Vries, Elisabeth G. E.
Lub-de Hooge, Marjolijn N.
de Vries, Erik F. J. http://orcid.org/0000-0002-6915-1590
Funding for this research was provided by:
Innovative Medicines Initiative (No 116106 (TRISTAN))
ZonMw (95104008)
Article History
Received: 20 March 2019
Accepted: 29 May 2019
First Online: 17 July 2019
Ethics approval and consent to participate
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Not applicable.
: G.A.P.H. reports other from MSD (advisory board), other from BMS (advisory board), other from Novartis (advisory board), other from Amgen (advisory board), other from Roche (advisory board), other from Pfizer (advisory board), grants from BMS, outside the submitted work; E.G.E.d.V reports grants from IMI TRISTAN (GA no.116106), during the conduct of the study; other from NSABP (consulting/advisory board), other from Daiichi Sankyo (consulting/advisory board), other from Pfizer (consulting/advisory board), other from Sanofi (consulting/advisory board), other from Merck (consulting/advisory board), other from Synthon Biopharmaceuticals BV (consulting/advisory board), grants from Amgen, grants from Genentech, grants from Roche, grants from Chugai Pharma, grants from CytomX Therapeutics, grants from Nordic Nanovector, grants from G1 Therapeutics, grants from AstraZeneca, grants from Radius Health, grants from Bayer, outside the submitted work; E.F.J.d.V. reports grants from ZonMW (GA no. 95104008), during the conduct of the study; grants from Dutch Cancer Foundation, other from Rodin Therapeutics (contract research), other from Lysosomal (contract research), other from Hoffmann-La Roche (contract research), other from Ionis Pharmaceuticals (contract research), outside the submitted work. All remaining authors have declared no conflicts of interest.